Please login to the form below

Not currently logged in
Email:
Password:

Hospira

This page shows the latest Hospira news and features for those working in and with pharma, biotech and healthcare.

Pfizer could raise ‘up to $15bn’ from consumer unit sale

Pfizer could raise ‘up to $15bn’ from consumer unit sale

of failed merger attempts with AstraZeneca and Allergan, the takeovers of Hospira and cancer specialist Medivation, and the divestment of Hospira’s infusions unit.

Latest news

More from news
Approximately 12 fully matching, plus 66 partially matching documents found.

Latest Intelligence

  • Innovation in merger control and the impact on the pharmaceutical sector Innovation in merger control and the impact on the pharmaceutical sector

    For example, in the Pfizer/Hospira merger, the Commission found that the proposed transaction raised competition concerns because Pfizer was developing a competing medicine to Hospira’s. ... Specifically, Hospira was selling Inflectra, an infliximab

  • Deal Watch October 2016 Deal Watch October 2016

    These two biosimilars were originally licensed by Hospira but when Pfizer acquired Hospira it terminated the agreement. ... For example in Europe both Pfizer (Hospira) in 2009 and Mundipharma in 2014 have rights to Celltrion's infliximab.

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    This first infliximab biosimilar was developed and manufactured by Celltrion and is marketed by various partners, notably Hospira under the brand name Inflectra and Mundipharma as Remsima.

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    The top major pharma mergers, acquisitions and collaborations during the month were led by the Pfizer/Hospira and Salix/Valeant deals. ... Majority acquisition. 380. Pfenex/ Hospira. PF582 -  LUCENTIS biosimilar candidate - wet age-related macular

  • Pharma deals in February 2015 Pharma deals in February 2015

    There are no approved biosimilars in the US where Hospira awaits approval of Remicade and Retacrit. ... No doubt Pfizer had hoped Hospira's persistent manufacturing problems were a thing of the past.

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics